Daily Archives: June 13, 2018

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health

SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) — Medibio Limited  (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.

The mobile app, named Medibio Inform, allows businesses to offer employees the chance to ‘check-in on their mental health’ through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. This allows employees of participating businesses using Fitbit devices to assess their mental health using both traditional assessments and biometric measures.  At this time, only Fitbit users that are enrolled in a Mental Health Check-In with their employer have access to use the Inform app.

Via the Inform app, Fitbit users will be able to process specific biometric features to create an objective view of their overall health. Once the user has authorized Medibio to access their Fitbit account, the Inform app then pulls in the sleep, activity and heart rate data that is associated with the user’s wearable account. Medibio uses its proprietary platform and algorithms to process the biometric data and reports to the user on a daily basis.

The additional compatibility of Inform working with data from more than 25 million Fitbit wearable technologies, along with already accepted compatibility with nearly 13 million Garmin devices, is timely as the company prepares for the general consumer availability coming later in 2018.

“We’re thrilled to give Fitbit users the ability to monitor their personal, objective biometric data to help manage their overall mental health and well-being,” said Jack Cosentino, CEO of Medibio. “With the addition of Fitbit to our portfolio of compatible wearables, this strengthens our footprint in the market, and supports our goal to make our technology accessible to as many consumers as possible.”

Medibio’s Fitbit-compatible app is available in the App Store and Google Play today for compatible Fitbit devices.   For more information, visit the company’s website at www.medibio.com.au.

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Perth (WA), and Minneapolis, MN (U.S.). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:   Website: www.medibio.com.au
Press Inquiries:
Josh Purdy
Medibio Limited
josh.purdy@medibio.com.au
T: 952-222-0551 ext. 204
M: 612-695-0168
Australian Media Enquiries:
Nicholas Hay
RES Publica
nhay@respublica.com.au
T: +61 475 792 917 // +61 2 8297 1503

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health

SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) — Medibio Limited  (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.

The mobile app, named Medibio Inform, allows businesses to offer employees the chance to ‘check-in on their mental health’ through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. This allows employees of participating businesses using Fitbit devices to assess their mental health using both traditional assessments and biometric measures.  At this time, only Fitbit users that are enrolled in a Mental Health Check-In with their employer have access to use the Inform app.

Via the Inform app, Fitbit users will be able to process specific biometric features to create an objective view of their overall health. Once the user has authorized Medibio to access their Fitbit account, the Inform app then pulls in the sleep, activity and heart rate data that is associated with the user’s wearable account. Medibio uses its proprietary platform and algorithms to process the biometric data and reports to the user on a daily basis.

The additional compatibility of Inform working with data from more than 25 million Fitbit wearable technologies, along with already accepted compatibility with nearly 13 million Garmin devices, is timely as the company prepares for the general consumer availability coming later in 2018.

“We’re thrilled to give Fitbit users the ability to monitor their personal, objective biometric data to help manage their overall mental health and well-being,” said Jack Cosentino, CEO of Medibio. “With the addition of Fitbit to our portfolio of compatible wearables, this strengthens our footprint in the market, and supports our goal to make our technology accessible to as many consumers as possible.”

Medibio’s Fitbit-compatible app is available in the App Store and Google Play today for compatible Fitbit devices.   For more information, visit the company’s website at www.medibio.com.au.

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Perth (WA), and Minneapolis, MN (U.S.). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:   Website: www.medibio.com.au
Press Inquiries:
Josh Purdy
Medibio Limited
josh.purdy@medibio.com.au
T: 952-222-0551 ext. 204
M: 612-695-0168
Australian Media Enquiries:
Nicholas Hay
RES Publica
nhay@respublica.com.au
T: +61 475 792 917 // +61 2 8297 1503

Taconic Biosciences Launches European Production of Diet Induced Obesity Model

RENSSELAER, N.Y., June 13, 2018 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, has launched local production of the Taconic diet induced obesity (DIO) model in Europe.

DIO mice are used to study metabolic disease and obesity because they exhibit elevated glucose, insulin, cholesterol, leptin, and corticosterone, thus mimicking many aspects and complications of human metabolic disease. The Diet Induced Obese (DIO) C57BL/6NTac remains a preferred metabolic model because when placed on a high fat diet, C57BL/6NTac develops more consistent and pronounced metabolic syndrome compared to other DIO models.

“Taconic’s commitment to providing its customers with the best animal model solutions means providing access to technically superior products.  Having local production for the European research community enables scientists to easily leverage the C57BL/6NTac for critical studies,” stated Dr. Megan MacBride, portfolio director for commercial models at Taconic. Taconic’s DIO mice will be available for immediate delivery in typical study sizes, saving researchers months of conditioning time, and allowing them to start studies faster.

Taconic has an extensive collection of genetically engineered models (GEMs) and non-genetically engineered models as well as custom model generation and colony management solutions.  To learn more about Taconic’s products and services, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Global Blockchain Services Firm WACHSMAN Recruits Key Executives from Jefferies and J.P. Morgan to Lead New Strategy Division

Wachsman amplifies service offerings beyond public relations and events management with first major agency expansion

NEW YORK, NY, June 13, 2018 (GLOBE NEWSWIRE) — Wachsman, one of the world’s leading blockchain professional services firms, has hired senior bankers from investment banks Jefferies and J.P. Morgan to lead a new blockchain strategy and advisory division. Formerly Senior Vice President, Technology Investment Banking Group at Jefferies, Michael Chang joins Wachsman as Managing Director Strategy and will lead the firm’s new Strategic Advisory Group in New York. Chang will be supported by Associate Director Franklin Bi, former Vice President and Blockchain Strategy Lead for J.P. Morgan’s Blockchain Center of Excellence. Wachsman’s Strategic Advisory Group will provide blockchain consulting and advisory services to Wachsman’s existing clients as well as publicly-traded corporations and privately-held companies globally.

CEO David Wachsman said: “Today is a landmark occasion for our rapidly growing company. We have exceeded our clients’ expectations with world-class public relations support and many of them have asked us to do more for them. With the experience and expertise that Michael and Franklin share, we now have the talent to offer a wider range of services. Subject matter expertise in this world-changing technology is extremely valuable, so we’re proud to have attracted some of the brightest minds in blockchain to lead our new Strategic Advisory Group.”

During his tenure at Jefferies, Chang founded and led the firm’s blockchain coverage effort where he developed and executed blockchain strategies for clients ranging from large corporations, to institutional investors, to emerging blockchain companies. Prior to Jefferies, Chang was a Director in the Mergers and Acquisitions Group at Bank of America Merrill Lynch and Vice President at Citigroup, where he advised on over $40 Billion in M&A and capital raising transactions. Michael holds a Master of Business Administration from Cornell University, where he was a Roy H. Park Leadership Fellow.

Wachsman Managing Director Strategy, Michael Chang said: “I’m honored to bring my experience advising some of the world’s largest companies to Wachsman in the fastest growing industry of our generation, blockchain. We can all see the growth trajectory for blockchain and digital assets, but organizations seldom have the experience to guide companies through how to best employ the technology. The Strategic Advisory Group will advise companies on how to accelerate their strategic objectives utilizing blockchain technology to better reach and serve their customers in new and exciting ways.”

Franklin Bi spent four years at J.P. Morgan leading business strategy and use case prioritization for blockchain initiatives across wholesale banking, custody and fund services, and capital markets. Bi was responsible for driving J.P. Morgan’s initial assessment of the impact of blockchain technology in 2015, co-authored the J.P. Morgan report, “Unlocking Economic Advantage with Blockchain,” and played a key role in initiatives such as J.P. Morgan’s Quorum project, crypto-asset strategy, and consortia engagement. Bi graduated from The Wharton School at the University of Pennsylvania with a Bachelor of Science in Economics.

Wachsman was founded by David Wachsman in December 2015 and has grown to employ 90 staff worldwide, with a client portfolio of some of the largest and indispensable companies and projects in the blockchain ecosystem, including CoinDesk, eToro, Dash, tZERO, Steemit, Bitfinex, Crypto Valley Association, and Lisk.

About Wachsman:

Wachsman is a leading professional services firm for the blockchain industry. Originally founded as a Public Relations agency in December 2015, Wachsman has expanded its service offerings to include Event Management and Strategic Advisory. The Strategic Advisory Group will be led by former Senior Vice President of Jefferies’ Blockchain Coverage Group, Michael Chang, and supported by former Vice President and Blockchain Strategy Lead at J.P. Morgan’s Blockchain Center of Excellence, Franklin Bi. Since the company’s founding, Wachsman has grown to 90 people with offices in New York City and Dublin. The firm has represented more than 100 blockchain-focused companies, including some of the largest brands in the industry. David Wachsman is the Founder and CEO of Wachsman. Emma Walker is the Managing Director of Wachsman Europe.

Amanda Woodward
Wachsman 
917-900-2738
amanda@wachsman.com

Siluria Technologies and Saudi Aramco Technologies Company join forces to maximize chemicals production

SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) — Saudi Aramco Technologies Company, a subsidiary of the world’s largest oil company, and Siluria Technologies, a leader in disruptive process technologies for the petrochemical and energy industries have executed a multi-plant technology license for the integration of Siluria’s proprietary technology (natural gas to olefins) with Saudi Aramco’s high-olefins cracking process technology.Siluria Technologies

Siluria’s natural gas-to-olefins technology, based on oxidative coupling of methane chemistry, is available for license in stand-alone configurations, as well as integration within a wide range of existing process plants; including steam crackers, propane dehydrogenation units, oil refineries, and methanol plants.    By integrating Siluria’s technology with existing facilities, operators can upgrade their methane-containing by-product streams from fuel to chemical value, improving carbon efficiency and production rates.

Robert Trout, Siluria’s President and CEO said, “Converting methane containing off-gases to higher value chemicals adds meaningful economic value, while plant integration can deliver excellent capital efficiencies.  We are thrilled to be working with a company like Aramco towards some of the largest and most technologically advanced petrochemical facilities the industry has ever seen.”

“As we engage more customers around the world, our clients are helping to discover new and exciting ways in which our technologies can be used to improve the economics, operability, and environmental footprint of their existing process plants,” added Trout.

Ahmad Al Khowaiter, Chief Technology Officer of Saudi Aramco commented, “Maximizing the output of high-value chemicals products from our future crude oil processing projects is one of the key objectives in our downstream technology strategy.”

He continued, “We see a strong fit with Siluria’s “gas to olefins” technology in certain plant configurations, and look forward to collaborating further with Siluria to realize the value of these processes.”

About Siluria:

Siluria Technologies is pioneering the commercial production of fuels and chemicals made from abundant natural gas and low value byproducts. Siluria’s proprietary technologies address the global petrochemical industry’s complex challenges of volatile commodity prices, shifting supply and demand patterns, stricter environmental regulations, and capitally intensive conventional technologies. Siluria’s revolutionary catalyst and process technologies uniquely combine nanomaterials, catalyst development, and chemical engineering, to convert natural gas into higher-value products through efficient processes that can be seamlessly integrated into existing industry infrastructure.

For more information about Siluria, visit www.siluria.com

About Saudi Aramco

Saudi Aramco is a world leader in integrated energy and chemicals, driven by the core belief that energy is opportunity. From producing approximately one in every eight barrels of the world’s crude oil supply to developing new energy technologies, our global team creates positive impact in all that we do. We focus on making our resources more sustainable and more useful, which promotes long-term economic growth and prosperity around the world.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba40bd87-c5dd-46da-9cba-832eae091fb1

Siluria Technologies
Beverly Jernigan
+1(713)494-1733
beverly@beverlypr.com

Contact
Saudi Aramco International Media Relations
Email: international.media@aramco.com

Presagis Launches New Modeling and Simulation Software Suite 17

MONTREAL, June 13, 2018 (GLOBE NEWSWIRE) — Presagis™ today released the newest version of its modeling and simulation (M&S) software portfolio, M&S Suite 17. Comprising industry-standard software such as Creator, Terra Vista, STAGE, Vega Prime, and Ondulus, M&S Suite 17 has added hundreds of new features and enhancements.

M&S Suite 17 provides an open, modular and standards-based simulation development framework designed to support a full range of applications across air, land, sea, for the defense, security and intelligence markets. Each product in the Suite offers new capabilities that support the Presagis focus on high-fidelity visuals, sensors and simulation.

Most of the significant enhancements were performed in direct response to the demands of Presagis customers.  With a focus on user workflow and performance, Presagis made hundreds of changes to parameters, options, and interfaces to help users work more logically, have more flexibility, and improve their user experience.

“When defining the M&S Suite 17 roadmap, we wanted to add enhancements that would be meaningful to our customers and build it according to how they work,” explains Stéphane Blondin, Presagis’ Vice President of Product Management and Marketing. “Today, our customers don’t work the same way they did ten, or even five, years ago. By understanding their workflows, needs, and limitations, we are able to provide tools, enhancements, and features that should benefit our users day in and day out.”

The M&S Suite 17 not only introduces major innovations but has also expanded with four  major additions:

Ondulus NVG: Building on the success of the Ondulus family of sensor products, Ondulus NVG now gives users the ability to add realistic physics-based night-vision sensor simulation to their research, training or mission planning environments.

Terra Vista Builder: Designed for customers operating large database production capabilities, Presagis created a new cost-effective version of Terra Vista that lets them independently build multiple projects at once on large server farms.

Ondulus Radar Pro: This offering of Ondulus Radar groups all previously existing radar modes and adds four new ones into a single competitive package.

3D Models Library: Featuring over a thousand high-quality models, this new simulation-ready asset library offers a rich mixture of military and civilian vehicles, weapons, vegetation, buildings and accessories that will help build large realistic simulation environments.

“The M&S Suite is a pillar in the Presagis portfolio. We continue to respond to our customers’ needs by providing new features and tools for content creators, as well as wider access and more development and scripting functionality for developers. We truly appreciate the loyalty of our customer base and want to make sure they always remain at the forefront of the performance and capabilities of the latest technology,” adds Blondin.

About Presagis

Presagis is a global leader providing commercial modeling, simulation and embedded software solutions to the aerospace, defense and security, and critical infrastructure markets. Presagis combines an open simulation development framework with expert professional services to help customers streamline development workflows, reduce project risks, and deliver game-quality immersive simulations. Presagis is also at the forefront of avionics software design for certifiable cockpit displays. The company serves hundreds of customers worldwide, including many of the world’s most respected organizations such as Boeing, Lockheed Martin, Airbus, BAE Systems, and CAE. For more information, visit www.presagis.com.

For further information: Stéphane Blondin, Vice President of Product Management and Marketing,
Tel: +1 514 341.3874, E-Mail: Stephane.Blondin@presagis.com

LEH Pharma announces first EyeMax Mono surgery performed in Argentina

LEH Pharma Ltd
(“LEH Pharma” or the “Company”)

LEH Pharma announces first EyeMax Mono surgery performed in Argentina

EyeMax now available in over 25 countries worldwide
Argentina represents significant market opportunity with 5.7 million aged 65 years or older

London, UK – 18 June 2018 — LEH Pharma Ltd, the leading provider of novel ocular implants for macular disorders, today announces that EyeMax Mono lens implant surgery for the treatment of age-related macular degeneration (AMD) has been successfully performed for the first time in Argentina. EyeMax is now being implanted by close to 100 surgeons in over 25 countries around the world.

The EyeMax Mono lens was implanted in both eyes by renowned ophthalmologist Dr Hugo Nano in Buenos Aires, Argentina. The EyeMax lens is the latest in LEH Pharma’s AMD lens portfolio and is unique in its ability to improve vision in patients at all stages of both dry and stable wet AMD. The product is delivered through a simple cataract surgery and is CE-marked and approved for sale in 34 countries across Europe and internationally.

AMD affects the central part of the retina and is the leading cause of blindness in people aged over 60, affecting nearly 200 million people worldwide. At present, only limited research has been conducted into the scale of AMD in Latin America, however available data suggests a high number of potential patients. Approximately 54 million people in Latin America and the Caribbean are over 65, and within this Argentina has one of the highest elderly populations in the region with up to 13.1% of the population, or 5.7 million, being 65 years or older1. The unique optics of the EyeMax lens optimises the quality of the image supplied across the macula, permitting patients to make use of functioning areas of retina that would otherwise receive a blurred image. It is the only adequate treatment for all types of AMD.

Dr Hugo Nano said: “It is wonderful to have brought the EyeMax Mono lens into Argentina for the first time. The operation was a success, and this patient will be the first of many to have their quality of life improved by LEH Pharma’s technology. AMD is one of the main causes of vision loss in the Argentinian population, so it is exciting to see this new treatment option become available through such a straightforward, quick operation.”

Dr Bobby Qureshi, CEO and founder of LEH Pharma, commented: “I am delighted that the EyeMax Mono lens will now be available to patients in Argentina, offering AMD sufferers in the country a chance for improved vision and a better quality of life. This expansion into an important new market underlines our focus on expanding the international reach of our products and services, and creating additional relationships with world-leading surgeons and ophthalmology specialists across the globe.”

For more information, please contact:

LEH Pharma Ltd
Dr Bobby Qureshi
contact@LEHPharma.com
+ 44 (0) 20 7060 2763

Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan, Chris Welsh
LEHPharma@consilium-comms.com
www.consilium-comms.com
+44 (0) 20 3709 5700

Notes for editors:

About LEH Pharma
LEH Pharma is a leading provider of revolutionary ocular implants for macular disorders. Its disruptive lens technology, which is unique, proven and patented, is currently marketed internationally for the treatment of stable wet and dry AMD. The Company was formed in 2011 by a group of pioneering surgeons, and is supported by a network of world-leading ophthalmologists and scientists.
For more information, please visit LEH Pharma’s website at www.lehpharma.com

About EyeMax
EyeMax is a revolutionary breakthrough for AMD sufferers and is the only adequate solution for the treatment of both the stable wet and dry form of the condition. EyeMax can be used in both eyes and can be applied fast and easily. The innovative technology and unique optics of the EyeMax lens enhances the quality of the image supplied to the all areas of the macula permitting patients with AMD to make better use of the healthier parts of their retina. Advantages of the product include safer surgery, ease of implantation and significant improvement of vision for patients2. Currently, the only other surgical options available for patients result in sub-optimal vision with high rates of complications. EyeMax is CE-marked in Europe and is exploring FDA approval in the US.

About age related macular degeneration (AMD)
LEH Pharma’s EyeMax product is aimed at improving the quality of life of patients with AMD, the western world’s biggest cause of blindness and the greatest unmet need in ophthalmology. AMD is a disorder affecting the central part of the retina, causing changes to central vision and making everyday tasks difficult.

EyeMax is aimed at two main patient populations: those who require cataract (where 1 in 3 patients or more may have some form of macular degeneration) and the non-cataract population including patients with AMD prior to cataract surgery or sufferers of other macular diseases such as diabetic eye disease.

2 Published data from several European centres supports the effectiveness of EyeMax and can be found on the website here (www.iolamd.com/clinical-data). Most recently the European Journal of Ophthalmology found EyeMax safe and observed improvements after surgery above those of standard implants.


1 Risk factors of age-related macular degeneration in Argentina; Maria Eugenia Nano et al; April 2013 [Available here]